CHMP recommends JINARC® (tolvaptan) for approval in EU: The first pharmaceutical treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Otsuka Pharmaceutical Co., Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended JINARC® (tolvaptan) for approval. This treatment has been recommended to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.

Read the full press release from Otsuka Pharmaceutical Co., Ltd.